Global Patent Index - EP 1272190 A2

EP 1272190 A2 20030108 - A USE OF GALANTAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE; TARGETING THE UNDERLYING CAUSE OF THE DISEASE

Title (en)

A USE OF GALANTAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE; TARGETING THE UNDERLYING CAUSE OF THE DISEASE

Title (de)

VERWENDUNG VON GALANTAMIN ZUR BEHANDLUNG DER ALZHEIMER ERKRANKUNG; ERMITTLUNG DER DER KRANKHEIT ZUGRUNDELIEGENDEN URSACHE

Title (fr)

UTILISATION DE GALANTAMINE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER CIBLANT LA CAUSE FONDAMENTALE DE LA MALADIE

Publication

EP 1272190 A2 20030108 (EN)

Application

EP 01919406 A 20010328

Priority

  • EP 0103551 W 20010328
  • US 19426200 P 20000403

Abstract (en)

[origin: WO0174364A2] Galantamine has be used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. The therapeutic drugs, including galantamine, that have been used to date for the treatment of Alzheimer's disease were thought to provide only symptomatic relief. It has now been shown that galantamine can be used for the treatment of the underlying cause of the disease.

IPC 1-7

A61K 31/55; A61P 25/28

IPC 8 full level

A61K 31/55 (2006.01); A61P 25/28 (2006.01)

CPC (source: EP)

A61K 31/55 (2013.01); A61P 25/28 (2018.01)

Citation (third parties)

Third party :

  • US 4663318 A 19870505 - DAVIS BONNIE [US]
  • WO 0030446 A1 20000602 - BONNIE DAVIS [US]
  • TRAYKOV L. ET AL: "3-12-24: Preliminary results of the efficacy of galanthamine on cognitive functions in patients with Alzheimer's disease (AD)", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 150, September 1997 (1997-09-01), pages S158, XP002969083
  • TRAYKOV L. ET AL: "Therapeutic efficacy of galanthamine in Alzheimers'd disease (AD) - preliminary study", EUROPEAN JOURNAL OF CLINICAL PGARMACOLOGY - ABSTRACTS OF THE 2ND CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS (EACPT), vol. 52, 17 September 1997 (1997-09-17) - 20 September 1997 (1997-09-20), pages A166/532, XP002969084
  • TRAYKOV L. ET AL: "THERAPEUTIC AFFICACY OF GALANTHAMINE (NIVALIN*) ON COGNITIVE DEFICIT IN ALZHEIMER'S DISEASE", CEREBROVASCULAR DISEASE, vol. 8, January 2000 (2000-01-01), pages 23 - 27, XP002969085
  • See also references of WO 0174364A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0174364 A2 20011011; WO 0174364 A3 20020516; AU 4651801 A 20011015; CA 2310990 A1 20001009; EP 1272190 A2 20030108

DOCDB simple family (application)

EP 0103551 W 20010328; AU 4651801 A 20010328; CA 2310990 A 20000627; EP 01919406 A 20010328